TY - JOUR T1 - High Expression of <em>c-Met</em>, <em>PKCλ</em> and <em>ALDH1A3</em> Predicts a Poor Prognosis in Late-stage Breast Cancer JF - Anticancer Research JO - Anticancer Res SP - 35 LP - 52 DO - 10.21873/anticanres.13924 VL - 40 IS - 1 AU - HITOMI MOTOMURA AU - YUKA NOZAKI AU - CHOTARO ONAGA AU - AYAKA OZAKI AU - SHOMA TAMORI AU - TAKA-AKI SHIINA AU - SHOTARO KANAI AU - CHIHIRO OHIRA AU - YASUSHI HARA AU - YOHSUKE HARADA AU - RYOKO TAKASAWA AU - TAKEHISA HANAWA AU - SEI-ICHI TANUMA AU - YASUNARI MANO AU - TSUGUMICHI SATO AU - KEIKO SATO AU - KAZUNORI AKIMOTO Y1 - 2020/01/01 UR - http://ar.iiarjournals.org/content/40/1/35.abstract N2 - Background/Aim: Co-expression of c-Met and ALDH1A3 indicates a poor prognosis in stage III-IV breast cancers and contributes to cell proliferation and tumor formation by ALDH1-positive breast CSCs. PKCλ is overexpressed and contributes to a poor prognosis in several cancers. Materials and Methods: A breast cancer genomics data set (METABRIC, n=2509) was downloaded and analyzed, as was the effect c-Met and PKCλ inhibitors on ALDH1high cell viability and tumor-sphere formation. Results: c-Met expression correlates with expression of PKCλ in breast cancer. Stage III-IV breast cancer patients with c-Methigh PKCλhigh ALDH1A3high have a poorer prognosis than patients with c-Metlow PKCλlow ALDH1A3low. Foretinib and auranofin suppressed cell viability and tumor-sphere formation by ALDH1high cells. These results suggest that c-Met and PKCλ are cooperatively involved in cancer progression and contribute to poor prognoses in breast cancer. Conclusion: c-Met and PKCλ are potentially useful prognostic markers and therapeutic targets in late-stage breast cancer. ER -